contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


qlife-wrap-up-from-interview-with-ceo-thomas-warthoe

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Qlife Holding AB er et medico teknisk selskab, der stræber efter at revolutionere markedet for kliniske biomarkør- og virustest. Ved at muliggøre test derhjemme som et supplement til test i sundhedssystemet, lettes adgang til vigtige sundhedsinformationer, hvilket kan bidrage til bedre behandling og potentielt forebygge sygdomme. De første testkapsler i virksomhedens brand, Egoo. Health Platform, blev CE-mærket til professionelt brug i begyndelsen af 2020. Virksomheden har patentbeskyttelse for centrale dele af sin teknologi. Det danske selskab er noteret på Nasdaq First North Stockholm.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Qlife Holding AB er en medicinsk teknologi virksomhed, der stræber efter at revolutionere markedet for kliniske biomarkører- og virustest. Ved at muliggøre test/diagnostik i hjemmet som et supplement til test i sundhedsvæsenet, lettes adgangen til vigtig helbredsinformation, som kan bidrage til bedre behandling og potentielt forebygge sygdomme. Qlife Holding blev dannet i oktober 2019 og modtog samme år certificeringen ISO 13485:2016, hvilket betyder, at Qlife opfylder alle krav til fremstilling og salg af in vitro diagnostiske analysatorer og reagenser. De første kapsler i virksomhedens produkt, Egoo.Health Platform, blev CE-mærket til professionel brug i begyndelsen af ​​2020. Virksomheden har patentbeskyttelse på centrale dele af sin teknologi.

Qlife Holding

Qlife: Wrap up from interview with CEO Thomas Warthoe

Qlife: Wrap up from interview with CEO Thomas Warthoe.
We had the pleasure of interviewing CEO Thomas Warthoe about the LOI (Letter Of Intent) with Chinese Biotech company Hipro today.&nbsp;
CEO Thomas Warthoe expect a collaboration deal in place by year end 2023. Focus for the deal is the shared vision on the importance of blood based diagnostic solutions in making hospital-at-home successful. Hipro want to broaden the scope, with further assays and assist Qlife with a min. of 2 assays.
When the deal is signed and published, Qlife will give further details about the content, funding and royalties. But focus will be on getting a CFDA approval for The Egoo Health system and assays. Hipro is interested in 3 assays, hereof the CRP, already out in Europe.&nbsp;
Qlife strategy long term is still - test-at-home, but in the short to medium term focus will be on hospital-at-home, which offers a new emerging opportunity and get an approval i China. Continue CE-mark process in Denmark and implement the concept in hospitals with pilots. Finally roll-out the system with Hipro i China and continue seeking partners in other emerging markets and start commercialization in the Nordics.
Listen to interview here: <a href="https://www.youtube.com/watch?v=77U29nVAd6M" target="_blank" rel="noopener">Qlife interview</a>
Disclaimer:
HC Andersen Capital receives payment from Qlife for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 9:30 PM 19-09-2023.
&nbsp;

Qlife Holding

Forum opdateringer